GlassScriptPhysician profile
Todd Alan Tegtmeier
NPI 1669573630
$1,208.49
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $196.32 | 2019 | |
| Pfizer INC. | $176.74 | 2019-2020 | |
| Novo Nordisk INC | $160.78 | 2019-2020 | |
| Amgen INC. | $146.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.01 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $87.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $61.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.67 | 2019 | |
| Amarin Pharma, INC. | $45.88 | 2019 | |
| Merck Sharp & Dohme LLC | $33.89 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $27.79 | 2019 | |
| Glaxosmithkline, LLC. | $26.00 | 2019 | |
| Lilly USA, LLC | $21.97 | 2019 | |
| Medtronic USA, INC. | $15.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.31 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $12.06 | 2019 | |
| Hikma Pharmaceuticals USA | $11.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Tegtmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.